Steinhagen succeeds Guillaume Jetten, who has served as CEO and played a key role in strengthening the company’s operational and scientific foundations during a period of growth and transformation.
The appointment marks a planned transition in leadership structure to continue to build on the company’s success. A combination of organic growth and targeted acquisitions has led Symeres to evolve into a fully integrated transatlantic partner, bringing together more than 500 scientists across nine global sites with decades of multidisciplinary expertise in chemistry, biology, ADME-tox and CMC. Steinhagen has a strong scientific background and commercial experience to drive positive business impact for Symeres in its next phase of growth.
Building on this foundation, Steinhagen will focus on advancing Symeres’ vision of being a crucial partner from discovery through development with its “One Symeres” integrated platform that serves strategic partnerships across biotech and pharma. His scientific background also aligns with the company’s widely recognised scientific expertise.
As a seasoned CEO, board director, and R&D executive, Steinhagen brings more than 25 years of experience across pharma, biotech and the CRO/CDMO sector. He joins from Lario Therapeutics, where he served as CEO and co-founder, as well as Venture Partner at Epidarex Capital. His previous positions include President R&D at Aptuit, where he was a key member of the leadership team responsible for the company’s growth and successful sale to Evotec AG in 2017. Prior to that, he acted as SVP and Head of Global Drug Discovery at Grünenthal and held senior roles at Sanofi-Aventis and Bayer Pharma.
Henning Steinhagen holds a PhD in Chemistry and earned an executive MBA degree from the IMD in Lausanne in 2018.
“I was drawn to Symeres because of its unique capabilities and legacy in delivering and supporting biopharma from inception to IND,” said Steinhagen. “The team brings together deep scientific depth and a way of working that is genuinely collaborative and responsive.”
“Recently, we have made strong progress in bringing together our teams, capabilities, and culture into one organization,” said Guillaume Jetten. “We are now seeing clear validation from our customers, who value the continuity, scientific depth, and collaborative approach we offer. I’m proud of what we’ve achieved and confident that Steinhagen will build on this momentum and lead Symeres through its next phase of growth.”
Source: chemanager-online.com
LEO Pharma has agreed to buy the worldwide rights to Tanabe Pharma’s drug in development for photosensitive genetic disorder treatment, bolstering the Danish company’s pipeline that has already undergone expansion this year.
Merck & Co. and Moderna announced encouraging results from a large clinical trial testing a new, personalized cancer treatment for melanoma, a serious form of skin cancer. The treatment, called intismeran, is made individually for each patient using their own tumor’s DNA. It’s designed to teach the immune system to recognize and attack cancer cells unique to that person.
Eurofins laboratories are supported by a dedicated analytical laboratory and an adjacent GMP warehouse, creating an integrated setup spanning development, analytical support, material management, and manufacturing readiness.
